61/100B51.365
USD
-0.33
(-0.64%)
Market Closed
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
Genmab A cash on hand 2002–2026What is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
Genmab A/S ADS had 1.86B USD in cash and short-term investments on 30 September 2026, down 45.5% on a year before. At the end of fiscal year 2025 it had 1.71B USD.
Last updated 8 Nov 2026 · Next report 16 Feb 2027
Cash on hand
Growth
| Fiscal year | Period ending | Cash on hand | Growth | Total debt | Net cash |
|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 1.86B | -45.47% | 5.20B | -3.34B |
| FY2025 | 31 Dec 2025 | 1.71B | -91.89% | 5.43B | -3.71B |
| FY2024 | 31 Dec 2024 | 21.10B | -25.00% | 1.03B | 20.07B |
| FY2023 | 31 Dec 2023 | 28.14B | +26.03% | 770.00M | 27.37B |
| FY2022 | 31 Dec 2022 | 22.32B | +15.44% | 597.00M | 21.73B |
| FY2021 | 31 Dec 2021 | 19.34B | +20.27% | 425.00M | 18.91B |
| FY2020 | 31 Dec 2020 | 16.08B | +46.56% | 319.00M | 15.76B |
| FY2019 | 31 Dec 2019 | 10.97B | +79.67% | 181.00M | 10.79B |
| FY2018 | 31 Dec 2018 | 6.11B | +12.60% | 0.00 | 6.11B |
| FY2017 | 31 Dec 2017 | 5.42B | +38.27% | 0.00 | 5.42B |
| FY2016 | 31 Dec 2016 | 3.92B | +12.27% | 0.00 | 3.92B |
| FY2015 | 31 Dec 2015 | 3.49B | +31.30% | 118.00K | 3.49B |
| FY2014 | 31 Dec 2014 | 2.66B | +70.88% | 355.00K | 2.66B |
| FY2013 | 31 Dec 2013 | 1.56B | +3.54% | 2.49M | 1.55B |
| FY2012 | 31 Dec 2012 | 1.50B | +36.63% | 5.66M | 1.50B |
| FY2011 | 31 Dec 2011 | 1.10B | -33.27% | 11.85M | 1.09B |
| FY2010 | 31 Dec 2010 | 1.65B | +29.09% | 133.72M | 1.52B |
| FY2009 | 31 Dec 2009 | 1.28B | +1,724.87% | 24.94M | 1.25B |
| FY2008 | 31 Dec 2008 | 70.01M | -98.10% | 14.70M | 55.31M |
| FY2007 | 31 Dec 2007 | 3.69B | +114.20% | 15.67M | 3.68B |
| FY2006 | 31 Dec 2006 | 1.72B | +37.63% | 18.21M | 1.71B |
| FY2005 | 31 Dec 2005 | 1.25B | +198.62% | 23.04M | 1.23B |
| FY2004 | 31 Dec 2004 | 419.57M | +35.82% | 29.00M | 390.56M |
| FY2003 | 31 Dec 2003 | 308.92M | +22.13% | 24.14M | 284.78M |
| FY2002 | 31 Dec 2002 | 252.95M | — | 13.78M | 239.17M |
| Quarter | Period ending | Cash on hand | Growth on a year before | Total debt | Net cash |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 1.86B | -45.47% | 5.20B | -3.34B |
| Q2 FY2026 | 30 Jun 2026 | 1.50B | -48.14% | 5.27B | -3.77B |
| Q1 FY2026 | 31 Mar 2026 | 1.52B | -43.75% | 5.35B | -3.83B |
| Q4 FY2025 | 31 Dec 2025 | 1.71B | -91.89% | 5.43B | -3.71B |
| Q3 FY2025 | 30 Sept 2025 | 3.41B | -80.30% | 142.00M | 3.27B |
| Q2 FY2025 | 30 Jun 2025 | 2.90B | -81.58% | 147.97M | 2.75B |
| Q1 FY2025 | 31 Mar 2025 | 2.70B | -90.86% | 138.04M | 2.57B |
| Q4 FY2024 | 31 Dec 2024 | 21.10B | -25.00% | 1.03B | 20.07B |
| Q3 FY2024 | 30 Sept 2024 | 17.32B | -37.08% | 987.00M | 16.33B |
| Q2 FY2024 | 30 Jun 2024 | 15.73B | -36.77% | 1.02B | 14.71B |
| Q1 FY2024 | 31 Mar 2024 | 29.58B | +20.53% | 1.01B | 28.57B |
| Q4 FY2023 | 31 Dec 2023 | 28.14B | +26.03% | 770.00M | 27.37B |
| Q3 FY2023 | 30 Sept 2023 | 27.53B | +15.71% | 793.00M | 26.73B |
| Q2 FY2023 | 30 Jun 2023 | 24.88B | +15.12% | 803.00M | 24.08B |
| Q1 FY2023 | 31 Mar 2023 | 24.54B | +22.79% | 829.00M | 23.72B |
| Q4 FY2022 | 31 Dec 2022 | 22.32B | +15.44% | 597.00M | 21.73B |
| Q3 FY2022 | 30 Sept 2022 | 23.79B | +26.92% | 629.00M | 23.16B |
| Q2 FY2022 | 30 Jun 2022 | 21.62B | +20.92% | 634.00M | 20.98B |
| Q1 FY2022 | 31 Mar 2022 | 19.99B | +10.53% | 416.00M | 19.57B |
| Q4 FY2021 | 31 Dec 2021 | 19.34B | +20.27% | 425.00M | 18.91B |
| Q3 FY2021 | 30 Sept 2021 | 18.74B | +7.29% | 437.00M | 18.31B |
| Q2 FY2021 | 30 Jun 2021 | 17.88B | +39.85% | 443.00M | 17.43B |
| Q1 FY2021 | 31 Mar 2021 | 18.08B | +848.91% | 378.00M | 17.71B |
| Q4 FY2020 | 31 Dec 2020 | 16.08B | +46.56% | 319.00M | 15.76B |
| Q3 FY2020 | 30 Sept 2020 | 17.47B | +57.14% | 337.00M | 17.13B |
| Q2 FY2020 | 30 Jun 2020 | 12.78B | +83.89% | 356.00M | 12.43B |
| Q1 FY2020 | 31 Mar 2020 | 1.91B | -72.10% | 25.59M | 1.88B |
| Q4 FY2019 | 31 Dec 2019 | 10.97B | +79.67% | 181.00M | 10.79B |
| Q3 FY2019 | 30 Sept 2019 | 11.12B | +88.57% | 188.61M | 10.93B |
| Q2 FY2019 | 30 Jun 2019 | 6.95B | +14.50% | 194.05M | 6.76B |
| Q1 FY2019 | 31 Mar 2019 | 6.83B | +19.80% | 199.43M | 6.63B |
| Q4 FY2018 | 31 Dec 2018 | 6.11B | +12.60% | 0.00 | 6.11B |
| Q3 FY2018 | 30 Sept 2018 | 5.90B | +13.73% | 0.00 | 5.90B |
| Q2 FY2018 | 30 Jun 2018 | 6.07B | +16.42% | 0.00 | 6.07B |
| Q1 FY2018 | 31 Mar 2018 | 5.70B | +20.01% | 0.00 | 5.70B |
| Q4 FY2017 | 31 Dec 2017 | 5.42B | +38.27% | 0.00 | 5.42B |
| Q3 FY2017 | 30 Sept 2017 | 5.18B | +31.49% | 0.00 | 5.18B |
| Q2 FY2017 | 30 Jun 2017 | 5.21B | +38.61% | 0.00 | 5.21B |
| Q1 FY2017 | 31 Mar 2017 | 4.75B | +36.10% | 0.00 | 4.75B |
| Q4 FY2016 | 31 Dec 2016 | 3.92B | +12.27% | 0.00 | 3.92B |
| Q3 FY2016 | 30 Sept 2016 | 3.94B | +22.99% | 0.00 | 3.94B |
| Q2 FY2016 | 30 Jun 2016 | 3.76B | +27.19% | 0.00 | 3.76B |
| Q1 FY2016 | 31 Mar 2016 | 3.49B | +18.52% | 59.00K | 3.49B |
| Q4 FY2015 | 31 Dec 2015 | 3.49B | +31.30% | 118.00K | 3.49B |
| Q3 FY2015 | 30 Sept 2015 | 3.21B | +21.49% | 178.00K | 3.21B |
| Q2 FY2015 | 30 Jun 2015 | 2.96B | +14.46% | 237.00K | 2.96B |
| Q1 FY2015 | 31 Mar 2015 | 2.95B | +16.42% | 296.00K | 2.94B |
| Q4 FY2014 | 31 Dec 2014 | 2.66B | +70.88% | 355.00K | 2.66B |
| Q3 FY2014 | 30 Sept 2014 | 2.64B | +59.79% | 415.00K | 2.64B |
| Q2 FY2014 | 30 Jun 2014 | 2.58B | +67.08% | 474.00K | 2.58B |
| Q1 FY2014 | 31 Mar 2014 | 2.53B | +69.85% | 535.00K | 2.53B |
| Q4 FY2013 | 31 Dec 2013 | 1.56B | +3.54% | 2.49M | 1.55B |
| Q3 FY2013 | 30 Sept 2013 | 1.65B | +40.10% | 156.71M | 1.49B |
| Q2 FY2013 | 30 Jun 2013 | 1.55B | +63.82% | 4.51M | 1.54B |
| Q1 FY2013 | 31 Mar 2013 | 1.49B | +46.27% | 4.73M | 1.48B |
| Q4 FY2012 | 31 Dec 2012 | 1.50B | +36.63% | 5.66M | 1.50B |
| Q3 FY2012 | 30 Sept 2012 | 1.18B | -2.85% | 7.39M | 1.17B |
| Q2 FY2012 | 30 Jun 2012 | 944.17M | -27.42% | 8.71M | 935.47M |
| Q1 FY2012 | 31 Mar 2012 | 1.02B | -29.51% | 10.31M | 1.01B |
| Q4 FY2011 | 31 Dec 2011 | 1.10B | -33.27% | 11.85M | 1.09B |
| Q3 FY2011 | 30 Sept 2011 | 1.21B | -28.08% | 13.38M | 1.20B |
| Q2 FY2011 | 30 Jun 2011 | 1.30B | +41.35% | 14.90M | 1.29B |
| Q1 FY2011 | 31 Mar 2011 | 1.44B | +34.65% | 16.41M | 1.43B |
| Q4 FY2010 | 31 Dec 2010 | 1.65B | +29.09% | 133.72M | 1.52B |
| Q3 FY2010 | 30 Sept 2010 | 1.69B | — | 19.65M | 1.67B |
| Q2 FY2010 | 30 Jun 2010 | 920.25M | — | 21.35M | 898.90M |
| Q1 FY2010 | 31 Mar 2010 | 1.07B | — | 23.06M | 1.05B |
| Q4 FY2009 | 31 Dec 2009 | 1.28B | — | 24.94M | 1.25B |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet
Common questions about Genmab A's cash
Source: Financial Modeling Prep